Small molecule drug development for rare genodermatoses – evaluation of the current status in epidermolysis bullosa

Small molecule drug development for rare genodermatoses – evaluation of the current status in epidermolysis bullosa

Abstract Background Hereditary epidermolysis bullosa (EB) comprises a heterogeneous group of rare genodermatoses, which are caused by mutations in genes involved in the maintenance of the structural and functional integrity of dermo-epidermal adhesion in various stratified epithelia. In severe varia...

Full description

Bibliographic Details
Main Authors: Verena Wally, Manuela Reisenberger, Sophie Kitzmüller, Martin Laimer
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Epidermolysis bullosa
Genodermatosis
Small molecules
Orphan drugs
Clinical trial
Case study
Online Access:http://link.springer.com/article/10.1186/s13023-020-01467-9

Internet

http://link.springer.com/article/10.1186/s13023-020-01467-9

Similar Items